140 related articles for article (PubMed ID: 17189417)
1. Systemic anthrax lethal toxin therapy produces regressions of subcutaneous human melanoma tumors in athymic nude mice.
Abi-Habib RJ; Singh R; Leppla SH; Greene JJ; Ding Y; Berghuis B; Duesbery NS; Frankel AE
Clin Cancer Res; 2006 Dec; 12(24):7437-43. PubMed ID: 17189417
[TBL] [Abstract][Full Text] [Related]
2. The systemic administration of lethal toxin achieves a growth delay of human melanoma and neuroblastoma xenografts: assessment of receptor contribution.
Rouleau C; Menon K; Boutin P; Guyre C; Yoshida H; Kataoka S; Perricone M; Shankara S; Frankel AE; Duesbery NS; Vande Woude G; Biemann HP; Teicher BA
Int J Oncol; 2008 Apr; 32(4):739-48. PubMed ID: 18360701
[TBL] [Abstract][Full Text] [Related]
3. Systematic urokinase-activated anthrax toxin therapy produces regressions of subcutaneous human non-small cell lung tumor in athymic nude mice.
Su Y; Ortiz J; Liu S; Bugge TH; Singh R; Leppla SH; Frankel AE
Cancer Res; 2007 Apr; 67(7):3329-36. PubMed ID: 17409442
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of MAPK kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vivo.
Huang D; Ding Y; Luo WM; Bender S; Qian CN; Kort E; Zhang ZF; VandenBeldt K; Duesbery NS; Resau JH; Teh BT
Cancer Res; 2008 Jan; 68(1):81-8. PubMed ID: 18172299
[TBL] [Abstract][Full Text] [Related]
5. Anthrax lethal toxin inhibits growth of and vascular endothelial growth factor release from endothelial cells expressing the human herpes virus 8 viral G protein coupled receptor.
Depeille P; Young JJ; Boguslawski EA; Berghuis BD; Kort EJ; Resau JH; Frankel AE; Duesbery NS
Clin Cancer Res; 2007 Oct; 13(19):5926-34. PubMed ID: 17908989
[TBL] [Abstract][Full Text] [Related]
6. The effects of anthrax lethal factor on the macrophage proteome: potential activity on nitric oxide synthases.
Kim J; Park H; Myung-Hyun J; Han SH; Chung H; Lee JS; Park JS; Yoon MY
Arch Biochem Biophys; 2008 Apr; 472(1):58-64. PubMed ID: 18269913
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of Virulizin, a novel biological response modifier (BRM) in a panel of human pancreatic cancer and melanoma xenografts.
Feng N; Jin H; Wang M; Du C; Wright JA; Young AH
Cancer Chemother Pharmacol; 2003 Mar; 51(3):247-55. PubMed ID: 12655444
[TBL] [Abstract][Full Text] [Related]
8. CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma.
Tse KF; Jeffers M; Pollack VA; McCabe DA; Shadish ML; Khramtsov NV; Hackett CS; Shenoy SG; Kuang B; Boldog FL; MacDougall JR; Rastelli L; Herrmann J; Gallo M; Gazit-Bornstein G; Senter PD; Meyer DL; Lichenstein HS; LaRochelle WJ
Clin Cancer Res; 2006 Feb; 12(4):1373-82. PubMed ID: 16489096
[TBL] [Abstract][Full Text] [Related]
9. Interstitial diphtheria toxin-epidermal growth factor fusion protein therapy produces regressions of subcutaneous human glioblastoma multiforme tumors in athymic nude mice.
Liu TF; Hall PD; Cohen KA; Willingham MC; Cai J; Thorburn A; Frankel AE
Clin Cancer Res; 2005 Jan; 11(1):329-34. PubMed ID: 15671563
[TBL] [Abstract][Full Text] [Related]
10. Novel protein targeted therapy of metastatic melanoma.
Frankel AE; Koo HM; Leppla SH; Duesbery NS; Vande Woude GF
Curr Pharm Des; 2003; 9(25):2060-6. PubMed ID: 14552326
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma.
Alfano RW; Leppla SH; Liu S; Bugge TH; Ortiz JM; Lairmore TC; Duesbery NS; Mitchell IC; Nwariaku F; Frankel AE
Mol Cancer Ther; 2010 Jan; 9(1):190-201. PubMed ID: 20053778
[TBL] [Abstract][Full Text] [Related]
12. Lupeol inhibits growth of highly aggressive human metastatic melanoma cells in vitro and in vivo by inducing apoptosis.
Saleem M; Maddodi N; Abu Zaid M; Khan N; bin Hafeez B; Asim M; Suh Y; Yun JM; Setaluri V; Mukhtar H
Clin Cancer Res; 2008 Apr; 14(7):2119-27. PubMed ID: 18381953
[TBL] [Abstract][Full Text] [Related]
13. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
14. Biological and biochemical characterization of anthrax lethal factor, a proteolytic inhibitor of MEK signaling pathways.
Bromberg-White JL; Duesbery NS
Methods Enzymol; 2008; 438():355-65. PubMed ID: 18413261
[TBL] [Abstract][Full Text] [Related]
15. Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase.
Koo HM; VanBrocklin M; McWilliams MJ; Leppla SH; Duesbery NS; Vande Woude GF
Proc Natl Acad Sci U S A; 2002 Mar; 99(5):3052-7. PubMed ID: 11867750
[TBL] [Abstract][Full Text] [Related]
16. Comparison of oral and transdermal administration of rasagiline mesylate on human melanoma tumor growth in vivo.
Meier-Davis SR; Dines K; Arjmand FM; Hamlin R; Huang B; Wen J; Christianson C; Shudo J; Nagata T
Cutan Ocul Toxicol; 2012 Dec; 31(4):312-7. PubMed ID: 22515841
[TBL] [Abstract][Full Text] [Related]
17. Catalytically inactive anthrax toxin(s) are potential prophylactic agents.
Gupta M; Alam S; Bhatnagar R
Vaccine; 2007 Dec; 25(50):8410-9. PubMed ID: 17980467
[TBL] [Abstract][Full Text] [Related]
18. Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011-vcMMAE) targeting GPNMB.
Pollack VA; Alvarez E; Tse KF; Torgov MY; Xie S; Shenoy SG; MacDougall JR; Arrol S; Zhong H; Gerwien RW; Hahne WF; Senter PD; Jeffers ME; Lichenstein HS; LaRochelle WJ
Cancer Chemother Pharmacol; 2007 Aug; 60(3):423-35. PubMed ID: 17541593
[TBL] [Abstract][Full Text] [Related]
19. Comparative toxicity and efficacy of engineered anthrax lethal toxin variants with broad anti-tumor activities.
Peters DE; Hoover B; Cloud LG; Liu S; Molinolo AA; Leppla SH; Bugge TH
Toxicol Appl Pharmacol; 2014 Sep; 279(2):220-9. PubMed ID: 24971906
[TBL] [Abstract][Full Text] [Related]
20. Development of a preclinical model of spontaneous human melanoma central nervous system metastasis.
Cruz-Munoz W; Man S; Xu P; Kerbel RS
Cancer Res; 2008 Jun; 68(12):4500-5. PubMed ID: 18559492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
